Aducanumab binding to Aβ1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core
Aducanumab, a human IgG1 antibody with plaque-clearing effects and modest clinical benefit, binds selectively to aggregated Aβ via the N-terminal region. Yet, the molecular details of how the antibody engages Aβ1-42 fibrils remain unresolved. Using magic-angle spinning NMR, we show that binding of aducanumab preserves the overall architecture of the Aβ1-42 fibril core while inducing significant st
